Table 3.
Changes in surface phenotypes of migrated monocytes
| Marker | TNF-α | IFN-γ | IL-1α | MIP-1α |
| CD11a | 96 ± 8 | 106 ± 16 | 76 ± 41 | 87 ± 9 |
| CD33 | 74 ± 49 | 105 ± 7 | 107 ± 16 | 165 ± 107 |
| CD45RA | 52 ± 53 | 134 ± 77 | 73 ± 65 | 63 ± 34 |
| CD45RB | 91 ± 7 | 86 ± 4 | 79 ± 44 | 84 ± 23 |
| CD45RO | 80 ± 9* | 98 ± 6 | 92 ± 8 | 78 ± 54 |
| CD49d | 92 ± 31 | 83 ± 26 | 81 ± 18 | 87 ± 21 |
| CD54 | 199 ± 55* | 111 ± 38 | 173 ± 27* | 76 ± 31 |
| CD62L | 88 ± 10 | 52 ± 39 | 105 ± 42 | 103 ± 16 |
| CD86 | 103 ± 25 | 219 ± 134 | 69 ± 25 | 90 ± 36 |
| HLA-DR | 86 ± 2* | 88 ± 18 | 87 ± 20 | 82 ± 52 |
The changes in individual surface markers after pretreatment of endothelial cells (ECs) with the indicated cytokines and chemokines are shown as percentages of control experiments with untreated ECs. All results were derived from at least three independent experiments for each cytokine or chemokine. HLA-DR, human leucocyte antigen-DR; IFN-γ, interferon-γ; IL-1α, interleukin-1α; MIP-1α, macrophage inflammatory protein-1α; TNF-α; tumour necrosis factor-α. *Statistically significant change (P < 0.05) compared with cells that migrated through untreated ECs.